These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1469394)

  • 21. [Utility of the study of the vegetative nervous system in the differential diagnosis between Parkinson's disease and multiple system atrophy].
    Rouco I; Gómez JC; Lezcano E; Aniel-Quiroga MA; Velasco F; Barcena J; Pérez Bas M; Hurtado P; Cruz Lachén M; Zarranz JJ
    Neurologia; 2006 Apr; 21(3):119-23. PubMed ID: 16575624
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U; Piccini P; Del Dotto P; Pavese N; D'Antonio P; Muratorio A
    Funct Neurol; 1992; 7(4):295-8. PubMed ID: 1427361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The motor response to sequential apomorphine in parkinsonian fluctuations.
    Hughes AJ; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1991 Apr; 54(4):358-60. PubMed ID: 2056323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
    Castillo JL; Miranda CM; Araya F; Sáez D
    Rev Med Chil; 1996 Mar; 124(3):301-6. PubMed ID: 9008941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute challenge with apomorphine and levodopa in Parkinsonism.
    Rossi P; Colosimo C; Moro E; Tonali P; Albanese A
    Eur Neurol; 2000; 43(2):95-101. PubMed ID: 10686467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Motor response to apomorphine in patients with Parkinson's disease with long-duration response to levodopa.
    Bonuccelli U; Napolitano A; Del Dotto P; Quattrone A
    Clin Neuropharmacol; 2002; 25(2):119-21. PubMed ID: 11981241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease.
    Sohn YH; Metman LV; Bravi D; Linfante I; Aotsuka A; Mouradian MM; Chase TN
    Neurology; 1994 Apr; 44(4):755-7. PubMed ID: 8164839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
    de la Fuente-Fernández R
    Clin Neuropharmacol; 1999; 22(4):216-9. PubMed ID: 10442251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J; Luquin MR; Obeso JA
    Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Apomorphine in Parkinson disease].
    Gilhus NE
    Tidsskr Nor Laegeforen; 1991 Oct; 111(26):3166-9. PubMed ID: 1948940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of increasing doses of apomorphine during stereotaxic neurosurgery in Parkinson's disease: clinical score and internal globus pallidus activity. Short communication.
    Stefani A; Stanzione P; Bassi A; Mazzone P; Vangelista T; Bernardi G
    J Neural Transm (Vienna); 1997; 104(8-9):895-904. PubMed ID: 9451721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Case report.
    Chou KL; Forman MS; Trojanowski JQ; Hurtig HI; Baltuch GH
    J Neurosurg; 2004 Mar; 100(3):553-6. PubMed ID: 15035294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease.
    Rodriguez M; Lera G; Vaamonde J; Luquin MR; Obeso JA
    J Neurol Neurosurg Psychiatry; 1994 May; 57(5):562-6. PubMed ID: 8201324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
    Linazasoro G
    Neurologia; 1994 Jan; 9(1):1-3. PubMed ID: 8161461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations.
    Nyholm D; Constantinescu R; Holmberg B; Dizdar N; Askmark H
    Acta Neurol Scand; 2009 May; 119(5):345-8. PubMed ID: 18822087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
    Hughes AJ; Lees AJ; Stern GM
    Lancet; 1990 Jul; 336(8706):32-4. PubMed ID: 1973218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
    De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apomorphine and diphasic dyskinesia.
    Durif F; Deffond D; Dordain G; Tournilhac M
    Clin Neuropharmacol; 1994 Feb; 17(1):99-102. PubMed ID: 8149366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The motor inhibition system in Parkinson's disease with levodopa-induced dyskinesias.
    Cerasa A; Donzuso G; Morelli M; Mangone G; Salsone M; Passamonti L; Augimeri A; Arabia G; Quattrone A
    Mov Disord; 2015 Dec; 30(14):1912-20. PubMed ID: 26275050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.